Non-hodgkin lymphoma: The clinician’s perspective—a view from the receiving end

Modern Pathology

Volumn 26, Issue , 2013, Pages 111-118

  Connors, Joseph M ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Lymphoid cancer treatment; Lymphoma classification; Non Hodgkin lymphoma

Indexed keywords

BEXAROTENE; BRENTUXIMAB VEDOTIN; CRIZOTINIB; HISTONE DEACETYLASE INHIBITOR; INTERFERON; METHOTREXATE; RITUXIMAB;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; B CELL LYMPHOMA; BONE MARROW BIOPSY; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DRUG MEGADOSE; FOLLICULAR LYMPHOMA; HISTOPATHOLOGY; HISTORY; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; MANTLE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; PERIPHERAL T CELL LYMPHOMA; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; REVIEW; SKIN LYMPHOMA; SPLENECTOMY; SPLENIC MARGINAL ZONE LYMPHOMA; TESTICULAR LYMPHOMA; TREATMENT PLANNING;

COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; HUMANS; LYMPHOMA, NON-HODGKIN;

EID: 84871906234     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.184     Document Type: Article

References (63)

1. Banerjee D, Gascoyne RD, Slack G, et al. Clinical impact of pathology reviews of outside material: a patient-focused approach. J Clin Oncol 2011;29: 4212-4213.
2. Lester JF, Dojcinov SD, Attanoos RL, et al. The clinical impact of expert pathological review on lymphoma management: a regional experience. Br J Haematol 2003;123:463-468.
3. Proctor IE, McNamara C, Rodriguez-Justo M, et al. Importance of expert central review in the diagnosis of lymphoid malignancies in a regional cancer network. J Clin Oncol 2011;29:1431-1435.
4. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the committee on Hodgkin’s disease staging classification. Cancer Res 1971;31:1860-1861.
5. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer: Lyon, 2008.
6. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011;377:42-51.
7. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008;26:4579-4586.
8. Stathis A, Chini C, Bertoni F, et al. Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. Ann Oncol 2009;20:1086-1093.
9. Wundisch T, Mosch C, Neubauer A, et al. Helicobacter pylori eradication in gastric mucosa-associated lymphoid tissue lymphoma: results of a 196-patient series. Leuk Lymphoma 2006;47:2110-2114.
10. Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, et al. Resistance of t(11;18) positive gastric mucosaassociated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet 2001;357:39-40.
11. Swanson TW, Meneghetti AT, Sampath S, et al. Handassisted laparoscopic splenectomy versus open splenectomy for massive splenomegaly: 20-year experience at a Canadian centre. Can J Surg 2011;54:189-193.
12. Katz SC, Pachter HL. Indications for splenectomy. Am Surg 2006;72:565-580.
13. Arulogun SO, Prince HM, Ng J, et al. Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation. Blood 2008;112:3082-3087.
14. Persky DO, Unger JM, Spier CM, et al. Phase II study of rituximab plus three cycles of CHOP and involvedfield radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol 2008;26:2258-2263.
15. Shenkier TN, Voss N, Fairey R, et al. Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J Clin Oncol 2002;20:197-204.
16. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood 2010;116:2040-2045.
17. Shipp MA, Harrington DP, Anderson JR, et al. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 1993;329: 987-994.
18. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857-1861.
19. Weisenburger DD, Savage KJ, Harris NL, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 2011;117:3402-3408.
20. Savage KJ, Chhanabhai M, Gascoyne RD, et al. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 2004;15:1467-1475.
21. Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009;27:511-518.
22. Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009;27:1209-1213.
23. Armitage J, Vose J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124-4130.
24. Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 2006;24:181-189.
25. Yamaguchi M, Kwong YL, Kim WS, et al. Phase II Study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-cell tumor Study Group Study. J Clin Oncol 2011;29: 4410-4416.
26. Savage KJ, Harris NL, Vose JM, et al. ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALKþ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008;111:5496-5504.
27. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:1812-1821.
28. Gambacorti-Passerini C, Messa C, Pogliani EM. Crizotinib in anaplastic large-cell lymphoma. N Engl J Med 2011;364:775-776.
29. Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N Engl J Med 2006;354: 2419-2430.
30. Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med 2006;354: 2431-2442.
31. Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. Blood 2004;104:3009-3020.
32. Song KW, Barnett MJ, Gascoyne RD, et al. Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes. Ann Oncol 2007;18: 535-540.
33. Sweetenham JW, Santini G, Qian W, et al. High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group. J Clin Oncol 2001;19:2927-2936.
34. Katsuya H, Yamanaka T, Ishitsuka K, et al. Prognostic index for acute-and lymphoma-type adult T-cell leukemia/lymphoma. J Clin Oncol 2012;30: 1635-1640.
35. Tsukasaki K, Hermine O, Bazarbachi A, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol 2009;27:453-459.
36. Nador RG, Cesarman E, Chadburn A, et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi’s sarcoma-associated herpes virus. Blood 1996;88:645-656.
37. Montoto S, Fitzgibbon J. Transformation of indolent B-cell lymphomas. J Clin Oncol 2011;29: 1827-1834.
38. Al-Tourah AJ, Gill KK, Chhanabhai M, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin’s lymphoma. J Clin Oncol 2008;26:5165-5169.
39. Sehn LH, Scott DW, Chhanabhai M, et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 2011;29: 1452-1457.
40. Laskin JJ, Savage KJ, Voss N, et al. Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxis. Leuk Lymphoma 2005;46:1721-1727.
41. Vitolo U, Chiappella A, Ferreri AJ, et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol 2011;29: 2766-2772.
42. Touroutoglou N, Dimopoulos MA, Younes A, et al. Testicular lymphoma: late relapses and poor outcome despite doxorubicin-based therapy. J Clin Oncol 1995; 13:1361-1367.
43. Moller MB, d’Amore F, Christensen BE. Testicular lymphoma: a population-based study of incidence, clinicopathological correlations and prognosis. The Danish Lymphoma Study Group, LYFO. Eur J Cancer 1994;30A:1760-1764.
44. Connors JM, Klimo P, Voss N, et al. Testicular lymphoma: improved outcome with early brief chemotherapy. J Clin Oncol 1988;6:776-781.
45. Ferreri AJ, Reni M, Zoldan MC, et al. Importance of complete staging in non-Hodgkin’s lymphoma presenting as a cerebral mass lesion. Cancer 1996;77: 827-833.
46. O’Neill BP, O’Fallon JR, Earle JD, et al. Primary central nervous system non-Hodgkin’s lymphoma: survival advantages with combined initial therapy? Int J Radiat Oncol Biol Phys 1995;33:663-673.
47. Krogh-Jensen M, F DA, Jensen MK, et al. Clinicopathological features, survival and prognostic factors of primary central nervous system lymphomas: trends in incidence of primary central nervous system lymphomas and primary malignant brain tumors in a well-defined geographical area. Population-based data from the Danish Lymphoma Registry, LYFO, and the Danish Cancer Registry. Leuk Lymphoma 1995;19: 223-233.
48. Sarazin M, Ameri A, Monjour A, et al. Primary central nervous system lymphoma: treatment with chemotherapy and radiotherapy. Eur J Cancer 1995;31A: 2003-2007.
49. Ferreri AJ, Reni M, Bolognesi A, et al. Combined therapy for primary central nervous system lymphoma in immunocompetent patients. Eur J Cancer 1995;31A: 2008-2012.
50. Freilich RJ, DeAngelis LM. Primary central nervous system lymphoma. Neurol Clin 1995;13:901-914.
51. Lachance DH, Brizel DM, Gockerman JP, et al. Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: short-duration response and multifocal intracerebral recurrence preceding radiotherapy. Neurology 1994; 44:1721-1727.
52. Glass J, Gruber ML, Cher L, et al. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 1994;81:188-195.
53. Fine HA, Mayer RJ. Primary central nervous system lymphoma. Ann Intern Med 1993;119:1093-1104.
54. Boiardi A, Silvani A, Valentini S, et al. Chemotherapy as first treatment for primary malignant non-Hodgkin’s lymphoma of the central nervous system preliminary data. J Neurol 1993;241:96-100.
55. Esik O, Ikeda H, Mukai K, et al. A retrospective analysis of different modalities for treatment of primary orbital non-Hodgkin’s lymphomas. Radiother Oncol 1996;38:13-18.
56. Whitcup SM, de Smet MD, Rubin BI, et al. Intraocular lymphoma. Clinical and histopathologic diagnosis. Ophthalmology 1993;100:1399-1406.
57. Smitt MC, Donaldson SS. Radiotherapy is successful treatment for orbital lymphoma. Int J Radiat Oncol Biol Phys 1993;26:59-66.
58. Plowman PN, Montefiore DS, Lightman S. Multiagent chemotherapy in the salvage cure of ocular lymphoma relapsing after radiotherapy. Clin Oncol (R Coll Radiol) 1993;5:315-316.
59. Evens AM, David KA, Helenowski I, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol 2010;28:1038-1046.
60. Navarro WH, Kaplan LD. AIDS-related lymphoproliferative disease. Blood 2006;107:13-20.
61. Ganti AK, Weisenburger DD, Smith LM, et al. Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience. Ann Oncol 2006;17: 920-927.
62. Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell lymphomas. Blood 2011;117: 2319-2331.
63. Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 2009;114:2273-2279.